The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Strangvac, a vaccine against equine strangles, has been granted marketing authorisation by the European Commission
Stockholm, August 16, 2021 – Intervacc AB (“Intervacc”) announced today that the European Commission has granted a Marketing Authorisation for Strangvac® within the European Union. Strangvac® is a vaccine against equine strangles, a highly contagious infectious...Intervacc receives confirmation of a positive outcome for Strangvac, a vaccine against equine strangles, from the VMD in the UK
Stockholm, July 2, 2021 – Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has give a positive outcome on their application for a Marketing Authorisation for Strangvac® within the UK. Strangvac® is...Intervacc receives positive CVMP opinion for Strangvac, a vaccine against equine strangles, in the EU
Stockholm, June 17, 2021 – Intervacc AB (“Intervacc”) announced today that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac® within the EU....Report from Annual General Meeting in Intervacc
Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 9 June 2021, at which the following resolutions were made. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherings, the Annual...Intervacc and the Karolinska Institutet sign a multi-year contract for the development of innovative animal health vaccines
Stockholm May 28, 2021 – Intervacc AB (publ) and the Karolinska Institute, KI, announce today that they have extended the contract for the development of a new generation of animal health vaccines using recombinant proteins. The three-year contract means that...Nyhetstjänster
